Drug news
CHMP recommends Pomalidomide Celgene as a treatment for Multiple Myeloma
Celgene International S�rl, a wholly-owned subsidiary of Celgene Corporation has announced that the European Medicines Agency�s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Pomalidomide Celgene in combination with dexamethasone for the treatment of relapsed and refractory Multiple Myeloma (rrMM) in patients who have received at least two prior therapies, including both lenalidomide and bortezomib, and have demonstrated disease progression while on their last therapy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins